Antidepressant Medications
| Name | Indication, starting dose, target symptoms, and affected neurotransmitters | Half-life (T1/2)
CYP450 enzyme |
Notes/Notable side effects/Precautions |
| SSRIs | |||
| Citalopram
(Celexa)
|
|||
| Escitalopram (Lexapro)
|
|||
| Fluoxetine
(Prozac)
|
|||
| Fluvoxamine
(Luvox)
|
|||
| Paroxetine
(Paxil)
|
|||
| Sertraline
(Zoloft)
|
|||
| SNRIs | |||
| Venlafaxine
(Effexor) |
|||
| Desvenlafaxine
(Pristiq) |
|||
| Duloxetine
(Cymbalta) |
|||
| Other | |||
| Mirtazapine
(Remeron) |
|||
| Trazadone
(Desyrel) |
|||
| Vilazodone
(Viibryd) |
|||
| Vortioxetine
(Trintellix) |
|||
| Bupropion
(Wellbutrin) |
This table includes the most commonly prescribed medications for depression. If there are other medications you would like to include for your reference you can add rows.
Mood Stabilizer Medications
| Name | Indication (FDA approval )&
Starting dose |
Half-life (T1/2)
CYP450 enzyme |
Notes/notable side effects/precautions/required diagnostics/therapeutic levels |
| Lithium | |||
| Carbamazepine (Tegretol) | |||
| Valproic Acid | |||
| Lamotrigine (Lamictal) |
This table focuses on the 4 medications mentioned in your Stahl (2021) textbook. You may add others you think are pertinent.
Use one reference from Stahl, S. M. (2021). Stahl’s essential psychopharmacology: Neuroscientific basis and practical applications (5th ed.). Cambridge University Press.
1. For each medication listed, complete the following:
a. Provide indication, starting dose target symptoms, and affected neurotransmitters.
b. Include half-life and CYP 450 enzyme information.
c. List notable side effects and precautions.
d. Link notable side effects to the associated pathway or neurotransmitter.
Provide 3 APA references within 5 years
